Advisor Group Holdings, Inc. Nymox Pharmaceutical Corp Transaction History

Advisor Group Holdings, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.28 - $0.74 $3,472 - $9,176	12,400 Added 155.0%	20,400 $6,000
Q1 2022 May 04, 2022	SELL	$1.21 - $2.0 $4,961 - $8,200	-4,100 Reduced 33.88%	8,000 $10,000
Q3 2021 Nov 05, 2021	BUY	$1.3 - $2.23 $12,350 - $21,185	9,500 Added 365.38%	12,100 $25,000
Q1 2021 May 13, 2021	SELL	$2.22 - $3.39 $3,552 - $5,424	-1,600 Reduced 38.1%	2,600 $6,000
Q4 2020 Feb 10, 2021	SELL	$1.84 - $2.83 $1,472 - $2,264	-800 Reduced 16.0%	4,200 $10,000
Q3 2020 Nov 12, 2020	SELL	$2.3 - $3.66 $15,869 - $25,254	-6,900 Reduced 57.98%	5,000 $12,000
Q2 2020 Aug 14, 2020	BUY	$2.1 - $4.6 $14,490 - $31,739	6,900 Added 138.0%	11,900 $42,000
Q1 2020 May 18, 2020	BUY	$1.69 - $3.88 $8,450 - $19,400	5,000 New	5,000 $12,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.